J Drugs Dermatol. 2023 May 1;22(5):507-508. doi: 10.36849/JDD.5058.
Intralesional 5-fluorouracil (5-FU) is a promising, yet sparsely studied alternative to surgical treatment for nonmelanoma skin cancer (NMSC).1 Previous studies of intralesional 5-FU have reported concentrations ranging from 30 to 50 mg/mL. To the best of our knowledge, this case series represents the first reported use of intralesional 5-FU 10.0 mg/mL and 16.7 mg/mL for NMSC.
A retrospective chart review identified 11 patients who received intralesional 5-FU 10.0 mg/mL and 16.7 mg/mL for 40 cutaneous squamous cell carcinomas and 10 keratoacanthomas. We describe the characteristics of these patients and calculate the clinical clearance rate of dilute intralesional 5-FU therapy for NMSC at our institution.
Dilute intralesional 5-FU successfully treated 96% (48/50) of the study lesions, providing complete clinical clearance in 82% (9/11) of patients across a mean follow-up time of 21.7 months. All patients tolerated their treatments well with no reported adverse effects or local recurrences.
The use of more dilute preparations of intralesional 5-FU for NMSC may be a means of reducing cumulative dose and dose-dependent adverse reactions while maintaining clinical clearance. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.5058.
局部注射氟尿嘧啶（5-FU）是一种有前途的替代手术治疗非黑色素瘤皮肤癌（NMSC）的方法，但研究较少。1 先前的局部注射 5-FU 研究报告的浓度范围为 30 至 50mg/ml。据我们所知，本病例系列代表了首次报道使用 10.0mg/ml 和 16.7mg/ml 局部注射 5-FU 治疗 NMSC。
回顾性病历审查确定了 11 名接受局部注射 5-FU 10.0mg/ml 和 16.7mg/ml 治疗的患者，用于治疗 40 例皮肤鳞状细胞癌和 10 例角化棘皮瘤。我们描述了这些患者的特征，并计算了我们机构使用低浓度局部注射 5-FU 治疗 NMSC 的临床清除率。
低浓度局部注射 5-FU 成功治疗了 96%（48/50）的研究病变，82%（9/11）的患者在平均 21.7 个月的随访中完全清除了病变。所有患者均耐受良好，无不良反应或局部复发报告。
对于 NMSC，使用更稀释的局部注射 5-FU 制剂可能是减少累积剂量和剂量依赖性不良反应的一种方法，同时保持临床清除率。J 皮肤病药物学杂志。2023;22(5):doi:10.36849/JDD.5058.
